Observia

[SPUR applications] There’s a thousand ways to leverage SPUR’s behavioral data. Do you know how much it can help you?   In just a few questions, SPUR delivers robust and actionable data on patients’ behavior. Learn how you can leverage it in the use cases below 👇   And if you want to see it for yourself, try the SPUR demo: spur.observia-group.com 

[SPUR en cardiologie] SPUR en pratique, ce sont les professionnels de santé qui en parlent le mieux ! L'article ci-dessous, coordonné par le Dr. Kamel Abdennbi, « Le modèle SPUR : un nouvel outil dynamique pour améliorer l’observance de nos patients porteurs de maladies chroniques en cardiologie » et publié dans Cardio H, la revue du Collège National des Cardiologues des Hôpitaux, détaille l’intérêt des sciences comportementales pour améliorer l’observance. En effet, le Dr. Abdennbi et ses équipes utilisent le questionnaire SPUR systématiquement dans le programme d’éducation thérapeutique en réadaptation cardiaque Atoutcoeur de l’Hôpital Léopold Bellan. Il précise ainsi : « Nous espérons que SPUR s’avèrera un outil précieux pour les professionnels de la santé afin de déterminer les risques comportementaux de chaque patient et de mettre en place des services de soutien qui correspondent à leurs motivations comportementales personnelles ». Si vous souhaitez en savoir plus sur l’usage de SPUR en cardiologie, écrivez-nous ! #cardiologie #sciencescomportementales #ETP

[Together for adherence] Morisky: a name that resonates for anyone working on adherence. For years, the Morisky Medication Adherence Scale (MMAS) has been the gold standard of our industry. Today, the MMAS and SPUR are coming together to create the next generation of adherence measurement tools.   We are thrilled to share that the company called adherence., who manages the MMAS, and Observia are partnering to explore the possibilities of combining their two tools, and support all healthcare stakeholders in improving adherence.   Philip Morisky, MBA, founder of The company called Adherence says: “The partnership between Observia Group and Adherence is driven by a shared goal: to improve patient outcomes through better adherence.  Together, these tools create a robust framework for understanding and improving medication adherence. The MMAS provides the initial assessment, identifying patients at risk of non-adherence. SPUR then offers a deeper dive, helping to uncover the underlying factors and tailor interventions accordingly. This combination ensures that healthcare professionals have all of the Information needed to support their patients effectively”. The first step of this partnership is to offer access to the MMAS on limited-use basis to students and researchers for non-funded research, as well as an access to SPUR. We are excited for the perspectives that this partnership offers! 

[On continue] L’aventure OSyS se poursuit ! Après 3 ans de collaboration entre Observia et PHARMA SYSTÈME QUALITÉ et au regard du succès de l’expérimentation OSyS, nous sommes ravis de poursuivre notre travail commun pour les prochaines années. Orientation Système Soins (OSyS) est un projet qui nous tient à cœur et pour lequel nous accompagnons PHSQ depuis 3 ans. Projet Article 51, OSyS permet aux pharmaciens d’officine d’orienter efficacement les patients se présentant au comptoir en premier recours, à travers 6 arbres décisionnels validés par la HAS et digitalisés au sein d’une plateforme numérique simple d’utilisation. 2 de ces arbres décisionnels ont fait leur entrée dans le droit commun en juin, pour la prise en charge des cystites et des angines. Une nouvelle avancée pour la prise en charge sécurisée des petits maux du quotidien par les pharmaciens ! L’Outil Numérique OSYS est en cours d’adaptation pour être en accord avec les exigences réglementaires du nouvel Arrêté, faciliter le triage et sécuriser la prise en charge des patients. Bravo à Martine COSTEDOAT, Nicolas Fauquet et PHSQ pour leurs efforts constants en ce sens. Lorsque l’expertise métier rencontre l’expertise numérique, c’est tout le système de santé qui en bénéficie !

[Getting together] Another year, another seminar! That's probably one of our favorite times of the year: spending quality time as a team, after 12 months of hard work! The mixed weather didn't stop Observians from having fun around board games, drinks and wild games of table football. What a great way to recharge batteries before summer break! (hoping that summer and warm weather will find their way to France someday... 😁)

[Webinar] As our co-founder Kevin Dolgin likes to say: “Medications only work if they get into the patient’s body”.   To learn about how understanding the drivers behind non-adherence can radically improve patient outcomes, come and listen to Kevin, Dr. Anoop Chauhan and Prof. Florian Limbourg during the "Spotlight on medication adherence" webinar, organized by Springer Medicine.   And if you still need to be convinced, just listen to Kevin tell you what you will learn during this webinar!   Register through the link in comments 👇

[SPUR & digital twins] Could digital twins help close the “clinical delta”: the difference between clinical and real world effectiveness? Yes, thanks to behavioral sciences.   🔎 How? That was the subject of a conference given by our co-founder and Affiliated Professor Kevin Dolgin and Professor Pablo Lamata from King’s College London during the Pharmaceutical Contract Management Group Annual Assembly. We thank our partner Clinical ink and Tim BEARPARK, MSc, MBA, DCR(T) for the introduction!   They discussed an issue faced by pharma companies in clinical trials: how to translate the evidence of a trial to real life? How to close the clinical delta between efficacy (ideal conditions) and effectiveness (real world)?   💡 Their answer: combining the digital models of physiology and health behaviors. Just as it is possible to create physiological models that predict the impact of medications on the body (absorption, distribution, metabolism, dose-response…), it is possible to use models based in behavioral science to predict adherence. In their own words, it would mean combining the model of a body and that of a head, to get the complete vision of a patient.   Physiological models could be used to determine side effects prevalence and dose-response curve at the population level, behavioral models such as SPUR could determine the impact of side effects on behavior and probable adherence for sub-populations or individuals. Together, they recapitulate real-world effectiveness and clinical data.   The knowledge could then help predict and improve real-world impact.   What is needed now is the procedures that systematically gather the data to refine the approach and make the two models play together. How exciting are these perspectives!

[Collaboration] Nous sommes ravis d’annoncer que Lilly France apporte son soutien institutionnel à la solution FormaRIC ! Issu de 18 mois de co-construction financée par le programme Innov’Up Expérimentation Santé, et déployé au sein de l’hôpital Cochin depuis le mois de mars, le projet FormaRIC accompagne les patients atteints de rhumatismes inflammatoires chroniques et leurs soignants. Le soutien apporté par Lilly viendra financer le déploiement dans d’autres centres, afin de permettre à de plus en plus de patients de toujours mieux se former et s’informer sur leur pathologie. Observia est fière de porter avec FormaRIC une forte ambition partenariale, autour d’un projet rassemblant déjà associations de patients, professionnels de santé et pouvoirs publics. Le futur de la santé est collaboratif, nous en sommes convaincus ! Nous remercions Lilly de leur confiance et de leur investissement dans une santé numérique au service de tous les patients. #FormaRIC #RIC #LillySEngage

[Article] Could digital therapeutics (DTx) have the potential to disrupt healthcare? Are they really the future of health interventions? For sure, #DTx offer many possibilities:  👉 Reduce healthcare costs  👉 Help improve #patients outcomes  👉 Reach a substantial market However, the wide accessibility of this new form of #healthcare calls for higher regulations, to ensure safe and efficient results. They are hard to deploy globally because of drastic differences in legal frameworks and reimbursement models: you can’t expect to launch a DTx in France in the same way you would in Germany! So what can be classified as #DTx? What norms must they meet? Are they worth the hype (and the investment)? ▶️ Find out more about DTx, their origins, their current applications, and their possible future:

[How to use SPUR] Are you in need of help to understand your patients and inform your decisions with objective data?   👉 That’s what the SPUR behavioral diagnostic tool provides.   Developed to be disease-agnostic and fully digital-by-design, the SPUR questionnaire has now been completed by more than 40,000 chronic #patients, in +25 therapeutic areas such as asthma, breast cancer, multiple sclerosis, and psoriasis, to name a few.   📈 SPUR data complements traditional approaches of patient understanding, by enriching it with behavioral considerations: Is my patient population at risk of being non-adherent? If so, why? Are there needs that were previously overlooked and that I could address? – are some questions you would now be able to answer.   Here’s below an example of a patient #persona built with SPUR and Observia’s market research methodologies, and inspired from a real-life case.   💡 Curious to see what it would look like in your strategic therapeutic areas? Drop us a line!